Bevacizumab plus irinotecan in recurrent glioblastoma - Reply

被引：4
|
作者：
Vredenburgh, James J. [1 ]
Desjardins, Annick
Reardon, David A.
Friedman, Henry S.
机构：
[1] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 06期
关键词：
D O I：
10.1200/JCO.2007.15.1746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1013 / 1013
页数：1
相关论文
共 50 条
  • [31] Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study
    Lu, Guangrong
    Rao, Mayank
    Zhu, Ping
    Liang, Buqing
    El-Nazer, Rasheda T.
    Fonkem, Ekokobe
    Bhattacharjee, Meenakshi B.
    Zhu, Jay-Jiguang
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [32] Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
    Desjardins, Annick
    Reardon, David A.
    Herndon, James E., II
    Marcello, Jennifer
    Quinn, JenniferA.
    Rich, Jeremy N.
    Sathornsumetee, Sith
    Gururangan, Sriclharan
    Sampson, John
    Bailey, Leighann
    Bigner, Darell D.
    Friedman, Allan H.
    Friedman, Henry S.
    Vredenburgh, James J.
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7068 - 7073
  • [33] EFFICACY OF BEVACIZUMAB PLUS IRINOTECAN IN CHILDREN WITH RECURRENT OR PROGRESSIVE MALIGNANT GLIOMA
    Arakawa, Yoshiki
    Umeda, Katsutsugu
    Watanabe, Ken-ichiro
    Mizowaki, Takashi
    Hiraoka, Masahiro
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Kunieda, Takeharu
    Takagi, Yasushi
    Miyamoto, Susumu
    NEURO-ONCOLOGY, 2014, 16 : 59 - 59
  • [34] Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme—improvement over available therapy?
    Sajeel Chowdhary
    Eric T Wong
    Nature Clinical Practice Neurology, 2008, 4 (5): : 242 - 243
  • [35] Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan
    Urup, Thomas
    Dahlrot, Rikke Hedegaard
    Grunnet, Kirsten
    Christensen, Ib Jarle
    Michaelsen, Signe Regner
    Toft, Anders
    Larsen, Vibeke Andree
    Broholm, Helle
    Kosteljanetz, Michael
    Hansen, Steinbjorn
    Poulsen, Hans Skovgaard
    Lassen, Ulrik
    ACTA ONCOLOGICA, 2016, 55 (04) : 418 - 422
  • [36] RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
    Gilbert, M. R.
    Wang, M.
    Aldape, K.
    Lassman, A.
    Sorensen, A. G.
    Mikkelson, T.
    Groves, M.
    Werner-Wasik, M.
    Regine, W.
    Mehta, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Radiographic evaluation of recurrent glioblastoma multiforme (GBM) in patients treated with bevacizumab and irinotecan
    Andre, J.
    Spearman, K.
    Lu, S.
    Hwang, S.
    Dorsett, L.
    Raval, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Radiographic evaluation of recurrent glioblastoma multiforme (gbm) in patients treated with bevacizumab and irinotecan
    Andre, Jalal
    Spearman, Kenneth
    Lu, Stanley
    Raval, Sumul
    NEURO-ONCOLOGY, 2007, 9 (04) : 575 - 575
  • [39] Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme - improvement over available therapy?
    Chowdhary, Sajeel
    Wong, Eric T.
    NATURE CLINICAL PRACTICE NEUROLOGY, 2008, 4 (05): : 242 - 242
  • [40] TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS
    Jakobsen, Jan Nyrop
    Urup, Thomas
    Grunnet, Kirsten
    Christensen, Ib Jarle
    Villingshoj, Mette
    Poulsen, Hans Skovgaard
    NEURO-ONCOLOGY, 2017, 19 : 6 - 6
12345